Seres Therapeutics Inc expected to post earnings of $1.28 a share - Earnings Preview

Reuters11-03

Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <mcrb.oq> expected to post earnings of $1.28 a share - Earnings Preview </mcrb.oq>

Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to show no change in quarterly revenue when it reports results on November 5 for the period ending September 30 2025
LSEG's mean analyst estimate for Seres Therapeutics Inc is for earnings of $1.28 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Seres Therapeutics Inc is $20.00, about 19.5% above its last closing price of $16.10

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jun. 30 2025	-2.53	-2.49	-2.27	Beat	8.9
Mar. 31 2025	-1.25	-0.54	-2.96	Missed	-448.1
Dec. 31 2024	-3.75	-3.94	-2.00	Beat	49.2
Sep. 30 2024	-4.88	-4.91	-7.60	Missed	-54.8
Jun. 30 2024	-5.46	-5.48	-4.40	Beat	19.7
Mar. 31 2024	-6.95	-6.82	-5.40	Beat	20.8
Dec. 31 2023	-7.95	-9.94	-6.40	Beat	35.6
Sep. 30 2023	-9.87	-10.03	-7.40	Beat	26.2

This summary was machine generated November 3 at 14:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580195932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580195932","market":"fut","top_or_hot":-1,"title":"Seres Therapeutics Inc  expected to post earnings of $1.28 a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <mcrb.oq> expected to post earnings of $1.28 a share - Earnings Preview </mcrb.oq></title></head><body><ul><li><p>Seres Therapeutics Inc <span>MCRB.OQ</span> <span>MCRB.O</span> is expected to  show no change in quarterly revenue when it reports  results on November 5 for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Seres Therapeutics Inc is for earnings of $1.28 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Seres Therapeutics Inc is $20.00, about 19.5% above its last closing price of $16.10</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-2.53</p></td><td><p>-2.49</p></td><td><p>-2.27</p></td><td><p>Beat</p></td><td><p>8.9</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-1.25</p></td><td><p>-0.54</p></td><td><p>-2.96</p></td><td><p>Missed</p></td><td><p>-448.1</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-3.75</p></td><td><p>-3.94</p></td><td><p>-2.00</p></td><td><p>Beat</p></td><td><p>49.2</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-4.88</p></td><td><p>-4.91</p></td><td><p>-7.60</p></td><td><p>Missed</p></td><td><p>-54.8</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-5.46</p></td><td><p>-5.48</p></td><td><p>-4.40</p></td><td><p>Beat</p></td><td><p>19.7</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-6.95</p></td><td><p>-6.82</p></td><td><p>-5.40</p></td><td><p>Beat</p></td><td><p>20.8</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-7.95</p></td><td><p>-9.94</p></td><td><p>-6.40</p></td><td><p>Beat</p></td><td><p>35.6</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-9.87</p></td><td><p>-10.03</p></td><td><p>-7.40</p></td><td><p>Beat</p></td><td><p>26.2</p></td></tr></tbody></table><p>This summary was machine generated November 3 at 14:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seres Therapeutics Inc  expected to post earnings of $1.28 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeres Therapeutics Inc  expected to post earnings of $1.28 a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <mcrb.oq> expected to post earnings of $1.28 a share - Earnings Preview </mcrb.oq></title></head><body><ul><li><p>Seres Therapeutics Inc <span>MCRB.OQ</span> <span>MCRB.O</span> is expected to  show no change in quarterly revenue when it reports  results on November 5 for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Seres Therapeutics Inc is for earnings of $1.28 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Seres Therapeutics Inc is $20.00, about 19.5% above its last closing price of $16.10</p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2025</p></td><td><p>-2.53</p></td><td><p>-2.49</p></td><td><p>-2.27</p></td><td><p>Beat</p></td><td><p>8.9</p></td></tr><tr><td><p>Mar. 31 2025</p></td><td><p>-1.25</p></td><td><p>-0.54</p></td><td><p>-2.96</p></td><td><p>Missed</p></td><td><p>-448.1</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-3.75</p></td><td><p>-3.94</p></td><td><p>-2.00</p></td><td><p>Beat</p></td><td><p>49.2</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-4.88</p></td><td><p>-4.91</p></td><td><p>-7.60</p></td><td><p>Missed</p></td><td><p>-54.8</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-5.46</p></td><td><p>-5.48</p></td><td><p>-4.40</p></td><td><p>Beat</p></td><td><p>19.7</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-6.95</p></td><td><p>-6.82</p></td><td><p>-5.40</p></td><td><p>Beat</p></td><td><p>20.8</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-7.95</p></td><td><p>-9.94</p></td><td><p>-6.40</p></td><td><p>Beat</p></td><td><p>35.6</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-9.87</p></td><td><p>-10.03</p></td><td><p>-7.40</p></td><td><p>Beat</p></td><td><p>26.2</p></td></tr></tbody></table><p>This summary was machine generated November 3 at 14:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MCRB","symbol_name":"Seres Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF18C:1","article_id":"2580195932","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580195932","pubTimestamp":1762178529,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Seres Therapeutics Inc  expected to post earnings of $1.28 a share - Earnings Preview Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to  show no change in quarterly revenue when it reports  results","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MCRB":"Seres Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Seres Therapeutics Inc预计每股收益为1.28美元-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCRB":0.9},"content_text":"Seres Therapeutics Inc  expected to post earnings of $1.28 a share - Earnings Preview Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to  show no change in quarterly revenue when it reports  results on November 5 for the period ending September 30 2025LSEG's mean analyst estimate for Seres Therapeutics Inc is for earnings of $1.28 per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Seres Therapeutics Inc is $20.00, about 19.5% above its last closing price of $16.10Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jun. 30 2025-2.53-2.49-2.27Beat8.9Mar. 31 2025-1.25-0.54-2.96Missed-448.1Dec. 31 2024-3.75-3.94-2.00Beat49.2Sep. 30 2024-4.88-4.91-7.60Missed-54.8Jun. 30 2024-5.46-5.48-4.40Beat19.7Mar. 31 2024-6.95-6.82-5.40Beat20.8Dec. 31 2023-7.95-9.94-6.40Beat35.6Sep. 30 2023-9.87-10.03-7.40Beat26.2This summary was machine generated November 3 at 14:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580195932","isCrawlerRequest":true}